Clarient Names Neal S. Goldstein, M.D. Director of Surgical Pathology

June 16, 2010

ALISO VIEJO, Calif., June 16 /PRNewswire-FirstCall/ — Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Neal S. Goldstein, M.D., has been named the Company’s Director of Surgical Pathology. He reports directly to Chief Medical Officer Kenneth J. Bloom, M.D.

Dr. Goldstein is a nationally known surgical pathologist with expertise in molecular pathology, immunohistochemistry, gastrointestinal pathology and breast pathology. Dr. Goldstein was most recently Laboratory Director at Redford, MI-based Advanced Diagnostics Laboratory and has also served as a consulting pathologist for Clarient for the past year.

“Dr. Goldstein is a thought leader in surgical pathology, immunohistochemistry, and molecular techniques, and his expertise enhances our ability to help our customers clarify the complexities of cancer, allowing for improved and more personalized care,” Dr. Bloom said. “He is a strong communicator, particularly among our pathologist clients, and has already shown his value as an important resource for us.”

From 2001 to 2008, Dr. Goldstein was Director of the Molecular Pathology Laboratory at Royal Oak, MI-based William Beaumont Hospital. From 1994 to 2008, he also served as Director of Immunohistochemistry at the hospital and was a member of its anatomical pathology lab.

Dr. Goldstein is listed as an author in more than 130 peer-reviewed publications, including journals such as Cancer, American Journal of Clinical Pathology, Urology, Histopathology, Journal of Surgical Oncology, several book chapters and many editorials. He has made presentations and has spoken at numerous conferences and educational forums. He was a member of the ER/PR (Estrogen Receptor and Progesterone Receptor) task force convened jointly by the College of American Pathologists and the American Society of Clinical Oncology and is an author of the recently published ER/PR testing guidelines.

Dr. Goldstein earned a bachelor’s degree in music from the University of Cincinnati’s College Conservatory of Music, studied pre-medicine at the University of Wisconsin, and graduated from the University of Wisconsin Medical School. He completed his internship and residency at the University of California at Los Angeles and a fellowship at Barnes Hospital in St. Louis.

Dr. Goldstein is board certified in Anatomic Pathology and Clinical Pathology.

About Clarient

Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient’s mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and development into better patient care. Clarient’s principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine has created the need for a centralized resource which provides leading oncology diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory, which provides advanced oncology testing and diagnostic services. Resulting diagnostic reports and analyses are made available to customers through Clarient’s Internet-based portal, PATHSiTE®. Clarient also plans to develop and market new, proprietary “companion” diagnostic markers for therapeutics in breast, prostate, ovarian, lung and colon cancers, and leukemia and lymphoma. www.clarientinc.com

Forward Looking Statements

Certain statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and Clarient’s actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: Clarient’s ability to continue to develop and expand its diagnostic services business, uncertainties inherent in Clarient’s product development programs, Clarient’s ability to expand and maintain a successful sales and marketing organization, Clarient’s ability to obtain additional financing on acceptable terms or at all, uncertainty of success in identifying and developing new diagnostic tests or novel markers, Clarient’s ability to fund development of new diagnostic tests and novel markers and the amount of resources Clarient determines to apply to novel marker development and commercialization, failure to obtain FDA clearance or approval for particular applications, Clarient’s ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, Clarient’s ability to obtain adequate patent protection covering its use of the TLE3 biomarker, the risk to Clarient of infringement claims and the possibility of the need to license intellectual property from third parties to avoid or settle such claims, Clarient’s ability to successfully validate and commercialize AGI’s product offerings, Clarient’s ability to commercially launch the Mammotax, Ovatax and Pulmotax tests, and other tests for taxane sensitivity in breast cancer and other carcinomas, beginning in the fourth quarter of 2010, and risks detailed from time to time in Clarient’s SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K.

Clarient does not assume any obligation to update any forward-looking statements or other information contained in this document.

    Investor Contact
    For Clarient:
    Matt Clawson
    Allen & Caron Inc
    (949) 474-4300

SOURCE Clarient, Inc.

Source: newswire

comments powered by Disqus